Meditative Neurofeedback for Depression

Launched by UNIVERSITY OF CALIFORNIA, SAN DIEGO · Nov 3, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new approach called meditative neurofeedback to help people who are experiencing moderate depression. Neurofeedback is a technique that teaches individuals to control their brain activity in a way that may improve their mood. The trial is open to both men and women aged 65 to 74 who have moderate symptoms of depression, as measured by a simple questionnaire called the PHQ9. However, individuals with certain conditions, such as active substance abuse, serious mental illnesses like bipolar disorder or psychotic disorders, or those who are acutely suicidal, won't be eligible to participate.

Participants in this study can expect to engage in sessions that focus on meditation and brain activity training. Since this is an open-label trial, everyone involved will know they are receiving the treatment. The study is currently recruiting participants, and it aims to explore whether this innovative approach can help improve mood and overall mental well-being in older adults facing depression. If you or someone you know fits the age and depression criteria, this could be an opportunity to explore a new treatment option.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • moderate depression per PHQ9 symptom ratings
• Exclusion Criteria:
• • active substance abuse/dependence
• • psychotic disorders
• • bipolar disorder
• • displaying acutely suicidal behaviors